communityacquir
respiratori
virus
carv
frequent
caus
upper
respiratori
infect
uri
adult
pediatr
popul
usual
occur
season
outbreak
healthi
outpati
morbid
caus
infect
minim
progress
lower
respiratori
tract
infect
lrti
rare
infect
selflimit
durat
although
case
report
viral
pneumonia
complic
hematopoiet
stem
cell
transplant
hsct
solid
organ
transplant
sot
describ
decad
recent
year
larger
case
seri
therapeut
trial
conduct
report
provid
greater
insight
impact
carv
immunosuppress
host
gener
observ
carv
infect
articl
focus
import
recent
literatur
specif
four
common
pathogen
respiratori
syncyti
viru
rsv
influenza
viru
parainfluenza
viru
piv
adenoviru
conclud
briefli
touch
sever
less
commonli
report
caus
viral
pneumonia
includ
potenti
import
emerg
pathogen
although
dozen
publish
studi
describ
epidemiolog
carv
find
often
wide
dispar
differ
part
result
natur
diseas
season
rel
frequenc
may
vari
depend
climat
report
institut
similarli
studi
track
singl
year
incid
carv
may
overor
underestim
gener
rel
frequenc
pathogen
base
particularli
widespread
epidem
singl
viral
pathogen
might
seen
year
especi
widespread
influenza
epidem
tabl
review
rel
frequenc
carv
sever
recent
report
depend
center
year
rsv
piv
influenza
common
pathogen
wherea
adenoviru
gener
account
fewer
carv
infect
final
studi
includ
children
may
report
higher
rate
carv
infect
focus
adult
popul
probabl
reflect
part
higher
carriag
carv
children
commonli
investig
employ
two
major
strategi
gain
understand
gener
epidemiolog
respiratori
viru
infect
first
consecut
tranplant
recipi
screen
regular
interv
usual
first
month
transplant
regardless
symptomatolog
result
studi
shown
overal
incid
rate
carv
infect
hsct
recipi
rang
contrast
recent
prospect
surveil
studi
sot
recipi
show
incid
carv
adult
liver
transplant
recipi
first
week
transplant
although
interpret
studi
limit
investig
use
throat
swab
alon
detect
carv
infect
frequent
publish
larg
retrospect
case
seri
carv
infect
seri
includ
patient
asymptomat
infect
overal
report
rate
carv
infect
predict
lower
rang
hsct
recipi
lung
transplant
recipi
although
larger
report
seri
repres
best
estim
carv
diseas
burden
gener
transplant
popul
import
rememb
report
bias
season
occurr
carv
nosocomi
commun
set
potenti
devast
impact
infect
hsct
sot
patient
major
limit
factor
understand
carv
infect
limit
sensit
current
wide
use
diagnost
test
three
patient
seri
involv
episod
symptomat
uri
hsct
recipi
fewer
half
patient
viru
isol
clinic
specimen
studi
clinic
center
use
combin
direct
dfa
indirect
ifa
fluoresc
antibodi
test
viral
cultur
result
fluoresc
antibodi
test
typic
avail
hour
viral
cultur
may
posit
day
children
test
often
perform
sampl
nasopharyng
lavag
adult
swab
nasopharynx
throat
often
substitut
wherea
dfa
ifa
test
may
sensit
carv
infect
immunocompet
host
two
studi
compar
ifa
viral
cultur
hsct
recipi
shown
composit
ifa
sensit
palmer
colleagu
report
dfa
sensit
seri
lung
tranplant
recipi
carv
infect
fluoresc
antibodi
test
viral
cultur
probabl
higher
yield
sampl
obtain
lower
respiratori
tract
one
recent
studi
two
third
carv
diagnos
made
bronchoalveolar
lavag
bal
sampl
recent
two
seri
use
realtim
polymeras
chain
reaction
pcr
assay
test
carv
infect
hsct
recipi
one
seri
adult
hsct
recipi
monitor
routin
nasal
throat
swab
period
realtim
pcr
posit
patient
wherea
viral
cultur
posit
mani
addit
posit
test
asymptomat
patient
rhinoviru
infect
brediu
colleagu
test
children
symptomat
respiratori
tract
infect
ifa
posit
viral
cultur
posit
realtim
pcr
posit
virus
perhap
especi
piv
often
copathogen
bacteri
fungal
infect
infect
carv
cytomegaloviru
aspergillu
speci
pneumocysti
jiroveci
describ
carv
pneumonia
convers
provid
may
halt
diagnost
workup
isol
singl
bacteri
fungal
pathogen
known
often
infect
tradit
oppor
tunist
pathogen
complic
coinfect
carv
overal
report
mortal
carv
infect
vari
wide
publish
seri
probabl
mortal
associ
directli
carv
infect
limit
upper
respiratori
tract
older
case
seri
predominantli
hospit
hsct
sot
recipi
lrti
mortal
frequent
greater
difficult
compar
seri
base
vari
definit
lrti
seri
posit
chest
radiograph
requir
defin
lrti
pneumonia
wherea
other
seri
physic
examin
find
eg
rale
hypoxia
consist
lower
tract
diseas
suffic
recent
seri
hsct
recipi
includ
outpati
uri
shown
much
lower
mortal
rang
raboni
colleagu
brazil
report
mortal
carv
infect
cohort
patient
mani
patient
receiv
allogen
bone
marrow
transplant
within
previou
year
fewer
case
seri
exist
sot
recipi
palmer
colleagu
report
mortal
seri
carv
lung
transplant
recipi
case
seri
renal
liver
transplant
recipi
show
mortal
infect
particular
recent
interest
possibl
link
carv
infect
develop
chronic
reject
lung
transplant
recipi
link
support
mous
model
piv
infect
aggrav
chronic
reject
lung
allograft
epidemiolog
possibl
carv
infect
contribut
chronic
lung
transplant
reject
manifest
bronchiol
obliteran
syndrom
bo
support
observ
bo
may
season
pattern
onset
observ
true
studi
howev
although
bo
occur
lung
transplant
recipi
year
overal
incid
rate
four
commonli
report
carv
gener
exceed
lung
transplant
cohort
note
previous
percentag
may
reflect
limit
current
diagnost
rather
lower
incid
infect
carv
infect
may
produc
wheez
bronchospasm
immunocompet
adult
surpris
case
seri
carv
infect
lung
transplant
recipi
report
declin
perform
pulmonari
function
test
acut
ill
two
report
follow
serial
pulmonari
function
test
sever
month
carv
infect
signific
chang
pulmonari
function
test
month
followup
although
one
investig
report
impair
pulmonari
function
persist
beyond
day
patient
three
report
demonstr
mark
variabl
rate
acut
reject
time
carv
infect
vilchez
colleagu
report
allograft
reject
patient
piv
infect
wherea
two
seri
report
acut
reject
patient
respect
time
carv
infect
studi
need
clarifi
import
dispar
two
larger
seri
specif
design
investig
link
carv
infect
bo
bear
closer
analysi
khalifah
colleagu
follow
adult
lung
transplant
recipi
prospect
identifi
carv
infect
nearli
lower
respiratori
infect
found
bronchoscopi
perform
either
surveil
respons
new
clinic
syndrom
patient
histori
carv
infect
cohort
like
develop
sever
bo
versu
die
bo
versu
die
caus
versu
patient
histori
carv
infect
addit
author
note
eight
patient
rsv
infect
three
treat
antivir
agent
develop
bo
wherea
four
five
patient
treat
antivir
agent
develop
box
bill
colleagu
follow
adult
lung
transplant
recipi
found
carv
infect
patient
followup
period
major
identifi
carv
infect
seri
lrti
mani
identifi
bronchoscopi
specimen
bronchoscopi
perform
surveil
followup
treatment
reject
seri
carv
lrti
found
predict
sever
grade
bo
moder
grade
bo
author
note
bo
clearli
risk
factor
carv
possibl
chronic
reject
facilit
colon
infect
progress
lrti
carv
also
probabl
howev
patient
bo
undergo
frequent
bronchoscopi
make
like
carv
infect
identifi
taken
togeth
report
khalifah
bill
strongli
suggest
associ
carv
infect
bo
signific
direction
associ
remain
determin
epidemiolog
rsv
occur
annual
late
autumn
winter
outbreak
gener
popul
low
level
persist
yearround
activ
season
pattern
found
hsct
recipi
like
carv
rsv
affect
children
adult
observ
confirm
singlecent
analys
adult
pediatr
hsct
program
coexist
epidem
natur
rsv
infect
must
stress
outbreak
respons
signific
morbid
mortal
sever
import
factor
may
contribut
rsv
outbreak
among
hsct
sot
recipi
inpati
unit
hsct
sot
recipi
tend
hous
dedic
ward
thu
expos
also
common
group
hospit
staff
care
provid
fall
winter
season
provid
may
shed
rsv
asymptomat
number
may
increas
commun
outbreak
addit
hsct
sot
recipi
like
immunocompet
patient
prolong
shed
rsv
thu
introduc
potenti
singl
index
case
infect
mani
patient
togeth
factor
may
explain
multipl
report
seri
rsv
infect
note
case
nosocomi
acquir
among
hsct
sot
recipi
rsv
commonli
report
carv
seri
see
tabl
larg
seri
rsv
infect
report
recipi
allogen
hsct
autolog
hsct
liver
transplant
lung
transplant
addit
case
report
small
seri
nearli
transplant
type
difficult
howev
compar
incid
report
trial
directli
studi
design
includ
longitudin
studi
singleyear
survey
prospect
surveil
data
mccarthi
colleagu
report
cumul
rsv
incid
allogen
hsct
recipi
period
small
colleagu
review
consecut
hsct
recipi
period
demonstr
incid
allogen
hsct
recipi
compar
autolog
hsct
recipi
report
confirm
higher
rate
allogen
hsct
recipi
includ
multicent
european
studi
show
singleyear
incid
symptomat
rsv
recipi
allogen
hsct
autolog
hsct
recipi
longitudin
studi
pediatr
liver
transplant
recipi
adult
lung
transplant
recipi
show
incid
rate
similar
longitudin
studi
respect
rsv
infect
begin
upper
respiratori
tract
cough
present
immunocompromis
patient
patient
also
report
rhinorrhea
sinu
congest
nearli
half
report
subject
wheez
although
fever
may
present
immunocompromis
patient
preval
fever
hsct
sot
recipi
well
clarifi
one
seri
patient
rsv
lrti
febril
morbid
mortal
rsv
directli
attribut
progress
infect
pneumonia
although
bacteri
infect
may
occur
coincident
carv
infect
seen
frequent
rsv
hsct
sot
recipi
mani
recent
seri
document
patient
rsv
infect
develop
pneumonia
present
pneumonia
other
develop
pneumonia
initi
present
uri
tabl
nearli
patient
present
pneumonia
give
histori
sever
day
anteced
uri
symptom
infect
progress
pneumonia
mortal
rate
high
result
sever
recent
report
present
tabl
show
hsct
recipi
rsv
pneumonia
die
diagnosi
rsv
infect
center
done
primarili
fluoresc
antibodi
test
wide
avail
test
ifa
dfa
rapid
turnaround
time
immunocompet
host
dfa
ifa
rsv
may
sensit
wherea
cultur
sensit
englund
colleagu
howev
report
concern
data
immunocompromis
adult
hematolog
malign
dfa
test
specimen
throat
swab
nasopharyng
wash
sensit
appli
specimen
bal
dfa
sensit
result
parallel
report
bill
colleagu
rsv
diagnos
made
bal
sampl
poor
yield
dfa
easili
obtain
sampl
highlight
need
newer
diagnost
test
strategi
preliminari
data
suggest
realtim
pcr
may
sensit
greater
rsv
infect
larg
seri
employ
diagnost
modal
howev
pcr
test
may
issu
falseposit
test
case
defin
posit
pcr
rsv
rsv
true
caus
patient
symptomatolog
definit
appropri
criterion
standard
test
may
prove
difficult
futur
studi
one
recent
seri
use
realtim
pcr
sampl
found
four
case
rsv
three
miss
viral
cultur
found
realtim
pcr
serolog
report
sensit
commerci
avail
ribavirin
synthet
guanosin
analogu
antivir
agent
activ
rsv
exact
role
treatment
hsct
sot
recipi
rsv
infect
remain
unclear
howev
dozen
studi
use
ribavirin
variou
formsintraven
oral
aerosolizedand
differ
point
ill
report
although
gener
mani
studi
difficult
preponder
data
suggest
benefit
ribavirin
therapi
may
augment
addit
nonspecif
rsvspecif
intraven
immun
globulin
benefit
demonstr
best
trial
use
aerosol
ribavirin
contrast
decidedli
mix
evid
oral
intraven
ribavirin
combin
therapi
endors
sever
set
consensu
guidelin
although
data
recommend
made
experi
treatment
hsct
recipi
reader
refer
excel
review
englund
colleagu
detail
summari
year
ribavirin
trial
rsv
infect
despit
recommend
favor
ribavirin
therapi
rsv
patient
popul
might
benefit
therapi
identifi
definit
note
previous
morbid
mortal
rsv
link
progress
infect
lower
respiratori
tract
sever
investig
therefor
sought
use
ribavirinbas
therapi
treatment
document
rsv
uri
recent
seri
ghosh
colleagu
small
colleagu
demonstr
low
rate
progress
pneumonia
hsct
recipi
rsv
uri
receiv
earli
therapi
ribavirin
intraven
immun
globulin
antivir
treatment
rsv
uri
specif
recommend
american
societi
transplant
howev
ghosh
small
seri
patient
progress
pneumonia
receiv
therapi
also
low
mortal
rate
comparison
histor
control
interestingli
benefit
therapi
establish
pneumonia
recommend
guidelin
clear
literatur
mortal
rate
sot
hsct
recipi
respiratori
failur
caus
rsv
pneumonia
estim
howev
least
one
consensu
group
favor
treatment
late
stage
import
highlight
potenti
difficulti
administ
aerosol
ribavirin
requir
smallparticl
nebul
machin
may
present
hospit
addit
ribavirin
tera
togen
pregnant
women
may
enter
room
patient
receiv
therapi
enter
room
includ
patient
may
develop
number
bothersom
side
effect
exposur
drug
includ
headach
rash
conjunct
potenti
barrier
drug
deliveri
best
address
advanc
provid
group
wish
ensur
time
administr
drug
patient
identifi
epidemiolog
piv
rsv
member
paramyxoviru
famili
unlik
rsv
four
major
serotyp
piv
caus
diseas
human
caus
annual
winter
outbreak
pattern
similar
rsv
influenza
wherea
circul
low
level
yearround
epidem
spread
frequent
seen
spring
summer
classic
caus
childhood
croup
wherea
associ
adult
diseas
lrti
pneumonia
epidemiolog
clearli
defin
least
commonli
isol
serotyp
case
rsv
epidem
piv
frequent
report
commun
dedic
hsct
unit
caus
signific
morbid
mortal
data
factor
contribut
epidem
set
limit
one
seri
report
piv
shed
month
two
hsct
recipi
piv
infect
account
carv
infect
recent
case
seri
hsct
sot
recipi
see
tabl
two
excel
longitudin
survey
piv
infect
hsct
recipi
publish
nichol
colleagu
fred
hutchinson
cancer
research
center
review
hsct
recipi
receiv
transplant
found
piv
infect
account
elizaga
colleagu
london
similarli
review
hsct
recipi
found
infect
unlik
report
rsv
hsct
recipi
piv
found
similar
frequenc
recipi
allogen
autolog
hsct
among
sot
recipi
case
seri
piv
report
renal
transplant
lung
transplant
recipi
lung
transplant
recipi
may
develop
piv
infect
although
may
asymptomat
infect
detect
frequent
bronchoscopi
lung
transplant
recipi
account
piv
isol
cough
hallmark
symptom
piv
infect
uri
symptom
eg
rhinorrhea
may
absent
fever
uncommon
lung
transplant
recipi
piv
lrti
febril
frequenc
lrti
recent
seri
piv
infect
hsct
recipi
review
tabl
overal
lrti
either
present
syndrom
progress
uri
report
one
third
patient
half
lrti
die
consider
variabl
exist
among
seri
patient
seri
least
case
piv
infect
rate
lrti
vari
mortal
among
patient
lrti
vari
importantli
larg
review
piv
infect
hsct
recipi
demon
diagnosi
piv
infect
usual
made
ifa
dfa
test
respiratori
secret
along
viral
cultur
notabl
wide
avail
fluoresc
antibodi
test
piv
test
may
explain
part
one
report
case
hsct
recipi
although
realtim
pcr
test
develop
yet
suffici
data
permit
comment
rel
use
comparison
convent
test
ribavirin
activ
piv
number
smaller
recent
report
ribavirin
given
hsct
recipi
piv
demonstr
lrti
mortal
rate
lower
histor
control
two
largest
seri
howev
demonstr
benefit
ribavirin
given
alon
combin
intraven
immun
globulin
furthermor
nichol
colleagu
demonstr
failur
ribavirin
therapi
shorten
durat
shed
time
recent
consensu
statement
infecti
diseas
commun
practic
american
societi
transplant
recommend
piv
lrti
provid
consid
aerosol
ribavirin
option
exist
experi
date
provid
littl
evid
efficaci
influenza
orthomyxoviru
one
common
communityacquir
respiratori
virus
signific
caus
morbid
transplant
recipi
actual
incid
influenza
transplant
recipi
unknown
mani
case
like
undiagnos
case
report
influenza
ill
probabl
overestim
sever
ill
popul
although
case
influenza
acquir
commun
set
nosocomi
acquisit
note
sot
hsct
unit
nosocomi
acquisit
often
associ
earlier
acquisit
transplant
case
like
result
wors
outcom
influenza
occur
season
basi
vast
major
case
occur
winter
month
influenza
b
describ
transplant
recipi
distribut
infect
mirror
commun
pattern
infect
influenza
viru
report
signific
pathogen
hsct
sot
recipi
among
sot
recipi
lung
transplant
recipi
may
special
risk
infect
transplant
recipi
document
persist
influenza
viral
shed
serv
potenti
signific
reservoir
viru
spread
other
commun
institut
set
time
influenza
infect
respect
transplant
significantli
affect
outcom
infect
sever
infect
occur
earlier
posttransplant
period
case
upper
respiratori
tract
symptom
predomin
lower
respiratori
tract
involv
uncommon
complic
influenza
includ
bacteri
superinfect
central
nervou
system
involv
myocard
transplant
reject
influenza
mortal
remain
low
influenza
suspect
individu
present
fever
rhinorrhea
coryza
myalgia
headach
winter
month
diagnosi
influenza
typic
reli
isol
viru
either
fluoresc
antibodi
techniqu
dfa
ifa
viral
cultur
nasal
oropharyng
epitheli
cell
sampl
obtain
nasal
lavag
pediatr
patient
swab
sampl
altern
bal
specimen
assay
serolog
diagnos
retrospect
may
limit
impair
humor
respons
recent
hsct
recipi
sot
recipi
especi
receiv
mycophenol
mofetil
sever
antivir
agent
demonstr
efficaci
influenza
use
vari
degre
transplant
recipi
amantadin
rimantadin
antivir
activ
limit
influenza
oseltamivir
zanamivir
activ
influenza
b
date
signific
drug
interact
report
medic
immunosuppress
therapi
includ
calcineurin
inhibitor
recommend
dosag
durat
treatment
normal
host
antivir
resist
report
rare
transplant
recipi
current
specif
recommend
alter
antivir
therapi
sever
fundament
differ
adenoviru
infect
infect
common
carv
adenoviru
may
acquir
persontoperson
transmiss
primari
respiratori
tract
infect
norm
rsv
piv
adenoviru
diseas
immunocompromis
patient
howev
probabl
reactiv
latent
infect
addit
adenoviru
infect
produc
wide
varieti
clinic
syndromesgastroenter
hepat
hemorrhag
cystitisin
addit
respiratori
tract
ill
pattern
ill
may
vari
host
adenoviru
serotyp
adenoviru
infect
account
carv
infect
recent
larg
case
seri
see
tabl
gener
adenoviru
common
children
infect
new
serotyp
may
primari
infect
like
produc
true
clinic
diseas
although
adenoviru
may
least
commonli
report
four
main
carv
infect
seri
import
recal
seri
test
patient
symptomat
uri
true
incid
adenoviru
infect
patient
popul
probabl
would
higher
clinic
manifest
includ
gener
three
pattern
adenoviru
infect
describ
hsct
sot
recipi
posit
sputum
test
adenoviru
infect
asymptomat
symptomat
respiratori
tract
infect
dissemin
diseas
without
respiratori
tract
involv
mortal
adenoviru
clearli
tie
dissemin
infect
dissemin
requir
progress
respiratori
tract
infect
therefor
unlik
rsv
piv
infect
mani
case
fatal
adenoviru
infect
report
patient
adenoviru
isol
upper
respiratori
tract
without
radiograph
evid
pneumonia
posit
test
lower
respiratori
tract
sampl
outcom
adenoviru
respiratori
tract
infect
hsct
poor
four
recent
seri
describ
mortal
rate
rang
cumul
mortal
case
although
mortal
adenoviru
pneumonia
high
noteworthi
one
third
death
occur
patient
adenoviru
uri
without
evid
pneumonia
fewer
case
adenoviru
infect
report
sot
recipi
detail
present
report
shed
import
light
natur
diseas
popul
mcgrath
colleagu
perform
largest
review
adenoviru
infect
adult
liver
transplant
recipi
show
overal
incid
rate
four
patient
posit
cultur
asymptomat
seven
clinic
diseas
three
pneumonia
evid
dissemin
diseas
make
unclear
pneumonia
primari
event
result
dissemin
uncontrol
infect
therefor
unclear
patient
seri
true
newli
communityacquir
respiratori
tract
infect
adenoviru
sever
paper
review
potenti
signific
adenoviru
infect
lung
transplant
recipi
approxim
lung
transplant
recipi
may
develop
adenoviru
infect
longitudin
studi
mani
patient
adenoviru
tie
close
graft
failur
acut
chronic
reject
number
patient
involv
prevent
rigor
statist
analysi
abil
draw
firm
conclus
two
largest
recent
seri
examin
potenti
link
bo
carv
infect
exampl
adenoviru
account
isol
adenoviru
infect
may
diagnos
use
wide
avail
immunofluoresc
antibodi
kit
test
insensit
adenoviru
sputum
howev
report
sensit
perhap
immunocompet
host
given
dfa
ifa
commonli
use
assay
lack
sensit
may
explain
part
rel
infrequ
adenoviru
survey
carv
infect
viru
cultur
well
identifi
readili
characterist
smudg
cell
histopatholog
adenoviru
frequent
may
reactiv
diseas
sensit
assay
perhap
pcr
base
may
detect
infect
frequent
studi
need
determin
whether
patient
indol
adenoviru
replic
actual
clinic
diseas
whether
anoth
pathogen
respons
clinic
present
wide
report
high
mortal
rate
adenovir
infect
particularli
earli
posttransplant
period
prompt
mani
clinician
push
earli
aggress
treatment
document
adenoviru
infect
hsct
sot
recipi
unfortun
limit
data
support
efficaci
avail
therapeut
recent
cidofivir
shown
improv
outcom
small
studi
children
hsct
anecdot
report
success
adult
signific
risk
nephrotox
associ
cidofivir
agent
use
caution
transplant
recipi
may
increas
risk
renal
impair
although
tri
past
neither
ribavirin
ganciclovir
demonstr
signific
efficaci
consequ
neither
agent
recommend
two
recent
articl
question
need
treatment
patient
document
adenoviru
infect
wall
colleagu
recent
report
result
retrospect
test
adenoviru
consecut
pediatr
hsct
recipi
seri
children
least
one
posit
test
adenoviru
spontan
clear
infect
without
antivir
therapi
two
children
die
dissemin
diseas
first
test
posit
first
week
hsct
recent
prospect
monitor
studi
van
kraaij
colleagu
hsct
recipi
also
demonstr
sever
case
earli
asymptomat
adenoviru
infect
rhinovirus
compris
serotyp
among
common
caus
common
cold
immunocompet
adult
children
studi
address
potenti
role
respiratori
pathogen
sot
hsct
recipi
avail
data
suggest
rhinoviru
infect
may
underappreci
four
studi
prospect
activ
surveil
carv
infectionon
adult
lung
transplant
recipi
one
pediatr
hsct
recipi
two
adult
hsct
recipi
note
rhinoviru
infect
cohort
two
studi
rhinoviru
common
isol
group
rhinoviru
infect
asymptomat
taken
togeth
three
longitudin
studi
hsct
recipi
symptomat
respiratori
tract
infect
identifi
rhinoviru
total
isol
report
case
symptomat
rhinoviru
respiratori
tract
infect
progress
lrti
two
lrti
death
attribut
rhinoviru
pneumonia
sever
seri
use
realtim
pcr
viral
surveil
newer
diagnost
technolog
becom
wide
use
true
epidemiolog
impact
rhinoviru
infect
hsct
sot
recipi
becom
clearer
present
specif
antivir
therapi
avail
treatment
rhinoviru
infect
coronavirus
like
rhinovirus
frequent
caus
benign
uri
occur
annual
wintertim
commun
outbreak
laboratori
isol
agent
difficult
systemat
studi
possibl
role
lrti
hsct
sot
recipi
undertaken
recent
experi
newli
identifi
caus
agent
sever
acut
respiratori
syndrom
sar
sar
coronaviru
bear
mention
kumar
colleagu
toronto
report
liver
transplant
recipi
die
sar
studi
tissu
obtain
autopsi
reveal
dramat
higher
concentr
sar
coronaviru
present
patient
tissu
case
patient
suggest
reason
fatal
cours
possibl
role
immunosuppress
patient
superspread
epidem
nearli
virus
herp
viru
famili
report
occasion
caus
pneumonia
hsct
sot
recipi
herp
simplex
viru
type
reactiv
almost
univers
hsct
sot
adult
latent
infect
sever
report
document
pneumonia
occasion
fatal
pathogen
suppress
effect
agent
use
cytomegaloviru
prophylaxi
howev
report
pneumonia
greatli
decreas
era
univers
prophylaxi
center
prophylact
acyclovir
given
suppress
reactiv
herp
simplex
diseas
even
recipi
donor
cytomegaloviru
neg
similarli
acyclovir
ganciclovir
activ
varicellazost
viru
vzv
report
rare
caus
pneumonia
sot
hsct
recipi
vzv
may
reactiv
point
posttransplant
cours
shingl
common
diseas
immunosuppress
popul
case
vzv
pneumonia
hsct
sot
recipi
preced
characterist
vesicular
skin
rash
vzv
pneumonia
rare
assum
prompt
antivir
therapi
acyclovir
abort
progress
reactiv
diseas
pneumonia
vzv
pneumonia
may
concern
children
adult
patient
innat
immun
vzv
either
natur
exposur
previou
vaccin
primari
vzv
infect
like
caus
pneumonia
final
role
human
herpesviru
human
herpesviru
pulmonari
pathogen
remain
poorli
understood
activ
replic
virus
detect
probabl
reactiv
latent
infect
hsct
sot
recipi
sever
author
report
isol
human
herpesviru
sputum
lung
tissu
patient
otherwis
idiopath
pneumonia
hsct
overal
data
howev
conflict
whether
caus
role
establish
ross
colleagu
report
seven
seven
lung
transplant
recipi
earli
bronchiol
obliteran
organ
pneumonia
three
four
patient
diffus
alveolar
damag
seri
detect
lung
transplant
recipi
patholog
biopsi
patient
acut
chronic
reject
ie
bo
find
thoughtprovok
confirm
need
research
potenti
role
singl
copathogen
certain
pattern
pulmonari
diseas
given
carv
infect
hsct
sot
recipi
occur
frequent
associ
poor
outcom
attent
must
given
prevent
carv
infect
recommend
multifacet
approach
prevent
morbid
mortal
infect
present
box
approach
prevent
carv
infect
must
start
appropri
hand
hygien
possibl
except
influenza
may
transmit
part
aerosol
droplet
carv
infect
transmit
larger
droplet
particl
introduc
host
oropharynx
hand
regular
hand
wash
attent
hand
wash
food
prepar
meal
significantli
reduc
incid
carv
infect
inpati
set
widespread
avail
alcoholbas
handwash
product
reduc
transmiss
hospitalacquir
infect
addit
infect
control
measur
recommend
prevent
spread
carv
infect
inpati
unit
center
diseas
control
prevent
recommend
contact
isol
patient
carv
infect
addit
droplet
precaut
taken
room
patient
adenoviru
influenza
respiratori
tract
infect
importantli
patient
place
special
precaut
infect
first
suspect
first
confirm
limit
exposur
patient
staff
infecti
droplet
measur
use
success
number
occas
limit
nosocomi
spread
carv
infect
one
group
report
reduct
rsv
case
hsct
unit
institut
droplet
precaut
cohort
case
patient
mani
author
includ
center
diseas
control
prevent
advoc
strongli
restrict
visitor
winter
month
well
infect
mani
carv
produc
measur
typespecif
antibodi
respons
respons
neither
long
last
protect
unfortun
trial
activ
vaccin
rsv
piv
disappoint
includ
trial
subunit
vaccin
live
attenu
virus
cortez
colleagu
recent
report
use
passiv
vaccin
pavilizumab
allogen
bone
marrow
transplant
recipi
although
titer
rsvspecif
immun
globulin
increas
differ
rate
rsv
infect
observ
prevent
influenza
transplant
recipi
focus
vaccin
transplant
recipi
among
immunosuppress
host
target
influenza
vaccin
standard
inactiv
vaccin
compos
two
influenza
one
influenza
b
strain
vaccin
composit
vari
annual
base
predict
antigen
drift
shift
circul
viru
consequ
annual
reimmun
recommend
optim
protect
live
attenu
intranas
influenza
vaccin
recommend
immunosuppress
host
includ
transplant
recipi
famili
health
care
provid
close
contact
patient
numer
studi
sever
decad
examin
vaccin
respons
transplant
recipi
demonstr
conflict
result
gener
humor
cellular
vaccin
respons
seem
suboptim
compar
healthi
control
reliabl
predict
base
level
immunosuppress
anecdot
report
suggest
potenti
linkag
vaccin
organ
reject
howev
associ
support
major
studi
examin
immunogen
vaccin
sot
recipi
current
recommend
support
annual
vaccin
sot
recipi
although
like
recent
transplant
may
less
like
respond
vaccin
hsct
recipi
may
especi
poor
vaccin
respond
within
first
year
transplant
prophylact
administr
licens
antivir
agent
includ
oseltamavir
zanamavir
may
serv
altern
prevent
measur
individu
unabl
receiv
influenza
vaccin
eg
egg
allergi
anticip
especi
box
approach
reduc
morbid
mortal
communityacquir
respiratori
viru
infect
hematopoiet
stem
cell
transplant
solid
organ
transplant
recipi
care
hand
hygien
especi
fall
winter
month
vaccin
patient
close
contact
particularli
influenza
avoid
contact
patient
symptomat
uri
patient
educ
eg
carv
infect
spread
avoid
sick
contact
perform
appropri
hand
hygien
combin
nasalthroat
swab
fluoresc
antibodi
test
earli
uri
consider
bronchoscopi
bal
sampl
symptom
progress
hsct
sot
patient
unexplain
lrti
pneumonia
routin
test
carv
infect
sot
hsct
recipi
present
pneumonia
includ
patient
alreadi
identifi
bacteri
fungal
pathogen
expand
use
newer
diagnost
tool
eg
realtim
pcr
awar
season
pattern
carv
infect
circul
virus
local
commun
patient
educ
eg
regard
need
contact
physician
uri
symptom
occur
consider
preemptiv
antivir
therapi
rsv
piv
uri
earli
posttransplant
period
specif
antivir
therapi
influenza
specif
antivir
therapi
influenza
aerosol
ribavirin
therapi
rsv
possibl
combin
intraven
immun
globulin
appropri
therapi
bacteri
fungal
coinfect
strict
adher
infectioncontrol
guidelin
hospit
includ
attent
hand
hygien
contact
droplet
aerosol
isol
dictat
accept
guidelin
consider
cohort
patient
inpati
unit
activ
surveil
case
find
infect
control
personnel
care
monitor
staff
visitor
symptom
uri
particularli
time
heighten
carv
preval
commun
separ
sick
healthi
patient
outpati
wait
area
unlik
respond
vaccin
although
specif
studi
transplant
recipi
antivir
agent
demonstr
effect
prevent
acquisit
influenza
administ
immunocompet
individu
period
peak
influenza
activ
transplant
recipi
may
suboptim
vaccin
respond
increas
risk
advers
outcom
influenza
consider
given
immun
household
contact
influenza
season
carv
frequent
caus
uri
lrti
hsct
sot
recipi
seri
rsv
piv
common
carv
signific
morbid
mortal
associ
infect
particularli
progress
lrti
outcom
also
poor
adenoviru
frequent
reflect
dissemin
infect
effort
prevent
morbid
mortal
carv
infect
focu
prevent
treatment
option
limit
inconclus
data
support
efficaci
